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MAG I N G I S P R E S E N T L Y I N T H E C R O S S H A I R S O F P O L I C Y M A K E R S in
he U.S. government as the health care reform debate rages on. The era of proving cost effectiveness, not just
fficacy, is upon us imagers whether we like it or not. Comparative effectiveness is the new buzzword in the
maging community. The debate in this issue of iJACC is about the utility of this standard to which newer
maging approaches are presently being held. Min et al. argue that this is a difficult standard, as assessing
utcomesbasedonadiagnostic test is fraughtwithdifficulty. Theypoint out the advantages and limitationsof
ingle-photon emission computed tomography (SPECT)myocardial perfusion imaging (MPI) as it grew into its
resent place in the diagnostic armamentarium. They suggest that computed tomography coronary angiog-
aphy (CTCA)has similar prognostic ability, at least in the intermediate term (long-termstudies areongoing), atlower cost. They recommend comparative effectiveness studies of CTCA and SPECTMPI.
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taymond Gibbons points out the problem of
piraling imaging costs. He sets the bar high for
TCA, namely defining its additive value to
xisting testing before encouraging widespread
doption. He too underscores the excellent
rognostic abilities of nuclear imaging. He
oints out limitations in the existing literature
egarding CTCA, including the relatively short
ollow-up periods for prognostic studies due to
he relative youth of the technology. Like Min
t al., he stresses the importance of clinical tri-
ls to compare CTCA to existing imaging
echnologies in the evaluation of patients with
uspected coronary artery disease (CAD). The
mphasis of comparative effectiveness by the
ational Institutes of Health and the American
eart Association (AHA), among others, will
opefully bear fruit in this regard. We at iJACC mope that you enjoy the vigor of this debate in
he imaging community. Both groups come to
he same conclusion: comparative studies are
orely needed.
ssessing the Value of Cardiac
maging: A New Era?
ames K. Min, MD, Rory Hachamovitch,
D, MSC, Alan Rozanski, MD, Leslee J.
haw, PHD, Daniel S. Berman, MD
AD is the primary cause of mortality, ac-
ounting for one-third of deaths in the U.S.
lone. Accurate diagnostic and prognostic as-
essment has been the mainstay of evaluating
atients at risk for these events, primarily
hrough functional imaging tests such as
yocardial perfusion SPECT (MPS). More
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306ecently, newer anatomic imaging mo-
alities, such as coronary computed to-
ographic angiography (CTA), have
hown promise for evaluation of pa-
ients with suspected or known CAD.
Nevertheless, the enthusiasm for
dopting such technologies has been
empered by a medical climate that in-
reasingly emphasizes cost containment.
pending on imaging by the Centers
or Medicare and Medicaid Services
CMS) more than doubled to $14 bil-
ion from 2000 to 2006 at 13% per
ear—almost twice that for other physi-
ian services, with cardiac imaging rep-
esenting a prominent component of
rowth (1). In light of such observa-
ions, many have proposed a new
enchmark for valuing cardiac testing,
amely, demonstration that testing
eads to improved outcomes at a rea-
onable cost. This concept of a “value-
ased health care system” has been im-
licitly adopted by CMS in a recent
roposed National Coverage Determi-
ation (NCD) of coronary CTA, which
alled for the satisfaction of 3 criteria—
ddressing diagnostic accuracy; resource
onsumption and costs; and clinical
utcomes—for demonstration of the
enefit of coronary CTA. A more con-
emporary adjunct to the proposed
CD has been advocated by the Medi-
are Payment Advisory Commission
nd culminated in the Comparative Ef-
ectiveness Research Act, which sug-
ested that newer technologies be sub-
ect to direct measure against pre-
xisting ones for demonstration of
omparative value, that is, both clinical
nd cost effectiveness (2).
These criteria transcend those re-
uired historically for noninvasive car-
iac testing, which have relied upon
easures of diagnostic accuracy and
rognostic risk stratification. As these
ecent shifts in perspective portend a
ew standard by which new imaging oechnologies may be considered, they
arrant closer examination.
otential approaches for assessing how
iagnostic tests affect outcomes. The
oncept of relating a diagnostic test to
uture clinical outcomes is not straight-
orward. By its inherent properties as a
iagnostic rather than therapeutic inter-
ention, an imaging test merely supports
linical decisionmaking and cannot by
tself directly improve outcomes. Imagin-
ng headlines proclaiming “Chest X-Rays
ure Pneumonia!” or “Nuclear Scans
revent Heart Attacks!” underscores the
bvious disconnect between supposed
ausal relationship between a diagnostic
est and clinical outcome, unless the test
ndings can be linked to physician and
atient behavior.
Instead, benefits from imaging are
ore easily measured by indirect means
Table 1). These measures fall into 5
eneral categories, including the impact
Table 1. Potential Measures of a Test’s Efﬁcacy
I. Traditional measures
1. Diagnostic accuracy (test sensitivity and
speciﬁcity)
2. Risk stratiﬁcation of events:
Cardiac death
Myocardial infarction
Other atherosclerotic outcomes (e.g., stroke)
All-cause mortality
II. Indirect measures
1. Changes in patient health practices
Physical activity
Eating habits and nutritional counseling
Smoking behavior
Adherence to medications
2. Physician-practice
Appropriate medication prescription
Appropriate ordering of downstream tests
Appropriate referral for coronary
revascularization
3. Soft clinical outcomes (e.g., quality of life)
4. Resource utilization
Physician visits
Number of subsequent hospitalizations or
emergency department visits
Medication prescriptions
Additional imaging tests
Revascularization procedures
5. Medical costsf testing on: 1) patient lifestyle or med- tcation compliance; 2) physician practice
ith scientific evidence; 3) improvement
n quality of life; 4) reduction in down-
tream resource utilization; and 5) reduc-
ion in health care costs. Collectively,
hese factors may reduce rates of adverse
vents. Many of these criteria of benefit
re not simple to assess since they are
ecessarily dependent on external factors,
uch as patient motivation, social sup-
ort, and “medical literacy;” quality and
uantity of medical support services; phy-
ician quality; and availability of medical
eimbursement. These numerous factors
reate a complex interplay that can dilute
he potential impact of any given testing
odality and challenge the quantification
f the indirect measures that are listed in
able 1.
This interchange between test, patient,
nd physician has caused some to ques-
ion whether diagnostic tests can or even
hould be held to the same standards as
herapeutic interventions. At present, no
lear guidelines exist for appraisal of new
iagnostic technologies under a value-
ased health care system. In fact, the
ost concrete method of assessing new
iagnostic technologies is defined by the
ood and Drug Administration (FDA)
pproval process—responsible for the au-
horization of new technologies for clin-
cal use—which is driven largely towards
eliability of manufacturer claims and pa-
ient safety, rather than improvement of
atient-centered outcomes. Thus, a crit-
cal gap exists such that the design of a
linical study to assess the value of a
iagnostic test may not be able to simul-
aneously satisfy the requirements set
orth by the FDA and advocates of
value-based” imaging.
It is within this context that we exam-
ne the emerging evidence for coronary
TA—which serves as an example of a
ewly introduced diagnostic technology
ith great promise—to determine what
urther evidence, if any, is required for
llustration of its utility to advocates of
he value-based imaging paradigm. We
egin with an examination of the evi-
ence accrued for SPECT MPI—a ma-
ure technology for which widespread
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307redence has developed with regards to
ts value—and use the SPECT MPI
vidence base as a template upon which
o guide future coronary CTA studies.
essons learned from SPECT MPI imag-
ng. Since its introduction over 30 years
go, SPECT MPI has become a main-
tay for diagnostic and prognostic assess-
ent of patients with suspected and
nown CAD. Numerous studies support
oth of these applications.
iagnostic efﬁcacy. A plethora of studies
nvolving a wide range of patient popu-
ations have documented the diagnostic
fficacy of SPECT MPI (3). Early diag-
ostic studies concerning SPECT MPI
ere performed with thallium-201; how-
ver, later studies confirmed the diagnos-
ic efficacy of subsequently developed ra-
iotracers such as Tc-99m sestamibi and
etrofosmin. One important lesson de-
ived from these studies is that diagnostic
erformance estimates are profoundly al-
ered when tests are used to guide patient
anagement, with systematic overesti-
ation of diagnostic sensitivity and un-
erestimation of diagnostic specificity.
otably, few studies have been per-
ormed with SPECT MPI in which
atients underwent the procedure for re-
earch purposes alone prior to invasive
oronary angiography (ICA)—an ap-
roach that reduces referral bias and has
ecome the standard approach used in
ssessing the diagnostic performance of
ore recently introduced modalities.
rognostic efﬁcacy. SPECT MPI also
emonstrates robust prognostic value,
ith incident CAD risk increasing expo-
entially with extent and severity of myo-
ardial perfusion abnormality. Based on
his relationship, semiquantitative seg-
ental scoring systems have been devised
o mirror gradations of risk. The prog-
ostic efficacy of SPECT MPI is widely
pplicable in numerous patient groups,
ncluding men and women, symptomatic
nd asymptomatic cohorts, diabetics, the
lderly, following revascularization, fol-
owing myocardial infarction, and in pre-
perative patients. The accrued evidence
n these diverse patient groups permits
ell-established practice guidelines and 1ppropriateness criteria that incorporate
PECT MPI in many clinical decision-
aking scenarios (3).
In principle, risk stratification is based
n the ability to discriminate patient risk
n the basis of a test result, and in this
egard, a normal SPECT MPI is
trongly associated with low risk, whereas
radations of risk can be identified with
rogressive levels of SPECTMPI abnor-
ality. Pooled data from published series
f patients with normal SPECT MPI
ndergoing a 2-year follow-up identi-
ed a cardiac death or nonfatal myocar-
ial infarction rate much lower than 1%
er year, corresponding to well-accepted
efinitions of “low risk” (3). As might be
xpected, the risk associated with any
evel of SPECT MPI abnormality varies
idely with baseline patient characteris-
ics, including patient age, diabetic state,
nability to exercise (i.e., pharmacologic
PECT MPI), abnormal rest electrocar-
iogram (ECG), prior CAD, and pres-
nce of dyspnea. In each of these patient
ubtypes, the findings of SPECT MPI
dd incremental value beyond the clinical
tate.
PECTMPI and beneﬁt from revasculariza-
ion procedures. Although abnormal
PECT MPI prognosticates heightened
isk of death and myocardial infarction, it
oes not necessarily follow that treatment
f these individual patients with abnor-
al tests results in reduction of events.
s the preponderance of CAD responsi-
le for myocardial infarction or sudden
ardiac death is due to nonobstructive
oronary artery plaques for which
PECT MPI would expected to be nor-
al, the challenge to demonstrate that
PECT MPI leads to improved patient
utcomes—consistent with a value-
ased health care system—has lead to a
ubtle but important shift in research
irection in the field. These more con-
emporary efforts have focused on
hether the SPECT MPI findings can
ssist in the determination of therapeutic
trategies with salutary effects on clinical
utcome.
In a large single-center registry of0,627 patients without prior CAD, rPECTMPI was examined for its ability
o determine image-based thresholds
hat can guide appropriate treatment
trategies (Fig. 1) (4). In matched co-
orts—adjusted for differences between
edically treated and revascularized pa-
ients and post-test referral patterns—
atients with extensive ischemia by
PECT MPI exhibited a clear survival
enefit when treated with revasculariza-
ion (Fig. 1). By contrast, among those
ith no ischemia, cardiac death rates
ere higher with revascularization than
ith medical therapy. The cut point at
hich ischemia tipped the balance to-
ards revascularization appeared to be
10% ischemic myocardium.
Another proof-of-principle, but never-
heless landmark study addressed how
PECT testing may shape clinical out-
omes in the nuclear substudy of the
OURAGE (Clinical Outcomes Utiliz-
ng Revascularization and Aggressive
rug Evaluation) trial (5). In this study
f 314 patients in whom both pre-
andomization and 6- to 18-month post-
andomization SPECT MPI was per-
ormed, patients assigned to percutaneous
oronary intervention and optimal medical
herapy (OMT) demonstrated greater
schemia reduction when compared with
atients receiving OMT alone (33% vs.
9%, p  0.0004). Importantly, the fre-
uency of adverse events was higher in
hose with greater post-treatment isch-
mia. Although this study was not de-
igned to prove that ischemia reduction
irectly reduces adverse CAD events, it
evertheless provides supportive evidence
hat imaging of ischemia does affect pa-
ient outcomes through guiding decisions
or revascularization.
Although prognostic SPECT MPI
ata were primarily derived from well-
erformed large-scale registries, there is
evertheless a dearth of evidence from
PECT MPI from primary analyses of
arge randomized trials. Furthermore, as
PECT-MPI evolved in an era that pre-
eded today’s highly cost-conscious envi-
onment, few studies have evaluated the
mpact of SPECT MPI on measures
elated to cost. Additionally, there are
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308lear limitations of SPECT-MPI: al-
hough it is clear that patients with nor-
al SPECT-MPI generally have an ex-
ellent prognosis, problems in guiding
ndividual patient management fre-
uently arise after abnormal SPECT-
PI. Further, if the patient has a high
re-test likelihood of CAD, a normal
PECT study does not rule out obstruc-
ive CAD. Particularly bothersome in
his regard are reports of underestimation
f left main coronary artery or triple-
essel CAD by SPECT. Problems also
rise in the substantial proportion of pa-
ients with equivocal or mildly abnormal
PECT studies. Although some early
ata suggested that medical management
ould be cost effective in this group as a
hole, more recent data have shown that
he hard cardiac event rates after testing
re not low in many subgroups of these
atients. Given these considerations, cli-
icians are often uncertain as to appro-
riate patient management following
PECT MPI.
ntroduction of coronary CTA: a new algo-
ithm of evaluation? Coronary CTA has
merged in a contemporary era, where
ocus on evidence development for car-
iac imaging transcends that which has
een developed for older technologies,
Figure 1. Log of Hazards Ratio Demonstrated Lo
Ischemic Myocardium Treated by Coronary Arte
Adapted with permission from Hachamovitch et al.nd instead proposes as necessary studies ln patient-centered outcomes and cost
ffectiveness prior to widespread use. In-
eed, critics of coronary CTA have sug-
ested that studies are needed to demon-
trate that use of coronary CTA provides
dditive value above and beyond that
hich is currently available. Although
he effect on patient outcomes has not yet
een shown with randomized trials, sev-
ral studies have assessed the clinical
enefit of coronary CTA.
iagnostic efﬁcacy. Despite rapid im-
rovements in CT technology, studies
valuating the diagnostic capability of
oronary CTA have kept pace, with
ewer studies evaluating the specific per-
ormance of coronary CTA with 64-
etector rows. Recent multicenter pro-
pective trials have also evaluated the
iagnostic performance of 64-detector
ow coronary CTA, confirming its high
iagnostic efficacy for CAD detection in
arying patient cohorts (6). Of note, the
iagnostic receiver-operator characteris-
ic curve area for detecting obstructive
AD, comparing coronary CTA with
CA, have shown clearly higher diagnos-
ic accuracy than with any other nonin-
asive test.
It should be noted that the diagnostic
ccuracy studies with coronary CTA are
Adverse Event Rates in Individuals with >10%
evascularization
Revasc  revascularization.ess limited by referral biases than those ihat have affected SPECT MPI results,
ince the decision to perform ICA on
hese patients was not governed by the
oronary CTA result. Nonetheless, biases
till remain as selected patients were al-
eady identified as needing ICA and
hus, had a relatively high pre-test likeli-
ood of CAD. Critics have noted that
he generalizability of coronary CTA
tudy results to patients with low or
ntermediate pre-test likelihood of
AD—where the test is more com-
only applied—is limited, although eth-
cal conduct precludes subjecting such
ndividuals to unnecessary invasive proce-
ures. Notably, the ACCURACY (As-
essment by Coronary Computed To-
ographic Angiography of Individuals
ndergoing Invasive Coronary Angiog-
aphy) trial, the only study to date per-
ormed in low-intermediate CAD prev-
lence cohort, reported high sensitivity
nd specificity of coronary CTA. The
CCURACY trial, however, also reveals
oth the strengths and inherent limita-
ions of testing with even a highly accu-
ate modality in a relatively low-
revalence population (6). The negative
redictive value (NPV) was extremely
igh (99%)—essentially ruling out the
resence of CAD; however, as predicted
y Bayes’ theorem, the positive predictive
alue (PPV) was low (35% to 45%). The
mplications of the negative coronary
TA are clear: the patient with a normal
tudy—free of coronary atherosclerosis—
an now be treated with high confidence
s not having CAD.
rognostic efﬁcacy. Given the recent in-
roduction of 64-row coronary CTA,
ong-term survival analyses are not yet
vailable. However, the predictive value
f coronary CTA to assess intermediate-
erm risk has now been studied. In a
ecent study of 1,127 patients undergoing
oronary CTA (7), gradations of risk for
ortality were evident by increasing cor-
nary artery plaque severity, location and
istribution (Fig. 2). These data are the
rst, to our knowledge, to demonstrate
hat coronary CTA is accurate for prog-
osticating mortality risk, although lim-wer
ry Rted by the small number of events re-
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309orded. The corollary to these findings is
hat a “normal” coronary CTA, as evi-
enced by no evident coronary artery
laque, conferred an exceptionally high rate
f survival of 99.7% in the 15-month
ollow-up (Fig. 2) (7). Additional evidence
sing electron beam CT suggests that the
warranty period” of a normal coronary
TA extends to at least 7 years (8).
A recent study provided the first com-
arison of coronary CTA and SPECT
PI to predict incident all-cause mortal-
ty (9). In a prospective evaluation of 541
atients undergoing both coronary CTA
nd SPECT MPI followed for 1.8 years,
he presence of CAD at the 50% stenosis
hreshold by coronary CTA demon-
trated equivalent predictive value for all-
ause mortality and nonfatal myocardial
nfarction, as compared with a summed
tress score (SSS) 4 by SPECT MPI.
nterestingly, the prognostic value of cor-
nary CTA was independent and syner-
istic to SSS 4 by SPECT MPI.
oronary CTA, resource utilization, and
ost effectiveness. To assess how coro-
ary CTA might influence resource uti-
ization and costs, 1,938 patients under-
oing coronary CTA were compared
ith 7,752 matched patients undergoing
PECT MPI (10). Downstream total
nd CAD costs for individuals undergo-
ng coronary CTAwere 27% (p 0.001)
nd 33% (p  0.001) lower compared
ith those undergoing SPECT MPI.
hese differences translated to a cost
avings for coronary CTA, beyond the
aseline test cost, of $445 (p  0.01).
Importantly, no differences existed be-
ween coronary CTA and SPECT MPI
ndividuals for rates of revascularization.
urthermore, individuals undergoing
oronary CTA or SPECT MPI as an
nitial diagnostic test did not differ in
ates of CAD hospitalization (4.2% vs.
.1%), myocardial infarction (0.4% vs.
.6%), or new-onset angina (3.0% vs.
.5%). As the specific test results were
ot available, direct comparison of the
elative cost effectiveness of these tests
annot be made. Nevertheless, to date,
he totality of studies evaluating the cost
fficiency of coronary CTA in individuals rithout known CAD indicates that it is
ost saving compared with SPECT MPI,
ithout differences in adverse CAD out-
omes.
uture directions. Coronary CTA has
een introduced during a time of spiral-
ng health care costs and reliance on
oninvasive imaging tests in cardiology.
hus, increased vigilance for unnecessary
esting is now desired, and the result
ppears to be the “raising of the bar” for
ew technologies such as coronary CTA.
s mentioned before, certain medical
olicy advocates now suggest that coro-
ary CTA, as well as other imaging
odalities, not only be subject to tradi-
ional measures of diagnostic and prog-
ostic efficacy, but also provide clear ben-
fit of patient-centered outcomes and
ost effectiveness. Data from large-scale
egistries will generate constructive
ypotheses, but randomized clinical
rials will be necessary to adequately
nswer the questions being posed. In
ddition, direct comparative effec-
iveness trials are necessary to evalu-
te new versus existing imaging tests
e.g., coronary CTA vs. SPECT
PI) and to study the ability of the
nformation derived from imaging to
uide patient management (e.g.,
PECT MPI-determined referral for
Figure 2. Decreasing Survival of Individuals Pos
Increasing Numbers of Major Epicardial Vessels
p  0.001 (controlling for risk factors and chest paevascularization). hAlthough initial coronary CTA stud-
es have begun to address these issues, full
xamination of benefit-oriented criteria is
omplex and more expensive to study
ompared with traditional assessments of
iagnostic performance and risk stratifi-
ation. Accordingly, funding entities now
alling for such study should also be
orthcoming with support of clinical trials
hat will be required to establish this new
ype of evidence.
he Health Care Crisis
aymond Gibbons, MD
n his speech to congress, on Febru-
ry 24, 2009, President Obama said:
. . .we must also address the crushing
ost of health care. . . .Health care reform
annot wait, it must not wait, and it will
ot wait another year” (11).
The President’s words eloquently
ummarize the growing realization that
he long-standing need for national
ealth care reform is more urgent every
ay. Although many politicians, and
ommentaries, focus on the problem of
he uninsured, the problem of escalating
osts is probably more important. As
hown in Figure 3, the annual growth in
oth public (federal and state) and private
ing Severe Coronary Artery Stenosis in
dapted with permission from Min et al. (7).sessealth care spending has consistently ex-
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310eeded the annual growth in gross do-
estic product (GDP) over the past 30
ears. The cumulative increase in private
ealth care spending is dramatically re-
ected in health insurance premiums
Fig. 4), which are now 320% of what
hey were in 1991. During the same time,
he Consumer Price Index has grown at
ess than half this rate. At least part of the
ncrease in private health insurance pre-
iums can be attributed to cost shifting,
s Medicare reimbursement has fallen
urther and further behind the cumula-
ive effects of inflation. Although the
ecrease in physician reimbursement that
s mandated by the Sustainable Growth
ate (SGR) formula has not occurred
ince 2002, the modest increases that
ave occurred since then have been far
ess than inflation, widening the gap be-
ween Medicare physician reimburse-
ent and inflation.
The crisis in health care costs will
oon get much worse, with the retire-
ent of the baby boom generation be-
inning in 2011. The combination of
his aging of the population and the an-
ual growth in health care spending
ill take an enormous toll on the fed-
ral budget (Fig. 5). By 2047, federal
pending on Medicare and Medicaid
ill exceed 20% of GDP. In the history
f our country, total federal revenue has
ever exceeded 20.9% of GDP. Thus,
y 2047, there will be no federal reve-
ue available for Social Security, interest
n the federal debt, aid to education,
efense, disaster aid, or anything else.
All of this “bad news” can be sum-
arized in a single statement: “The
urrent system is not sustainable”
12,13).
Imaging, particularly high-technology
maging, is part of the problem. The
se of CT, magnetic resonance (MR),
nd positron emission tomography
PET) increased from 42 procedures
er 1,000 Medicare beneficiaries in
995 to 163 procedures per 1,000 dedicare beneficiaries in 2005 (Fig. 6),
nearly 4-fold increase. This com-
ounded annual increase of 16% per
ear predated the use of CTCA. Other
ardiac imaging procedures have also
ncreased at a surprising rate. Between
993 and 2001, stress imaging (stress
PECT imaging and stress echocardi-
graphy) increased in Medicare patients
t an annual rate of 6% per year, which
as far in excess of the increase in car-
iac catheterization, revascularization, or
cute myocardial infarction (14).
Congress is increasingly concerned
bout the growth of imaging. Medicare
eimbursement for the technical com-
onent of high-technology imaging ser-
ices was reduced in early 2006. In
008, Congress mandated that the Sec-
etary of Health and Human Services
evelop an imaging appropriateness
emonstration project by 2010 and that
ll imaging laboratories performing ser-
ices under Medicare be accredited by
012. The National Priorities Partner-
hip, which includes multiple federal
gencies, multiple consumer groups, the
ARP, the U.S. Chamber of Com-
erce, and the National Quality Forum
which includes both the American
ollege of Cardiology [ACC] and the
merican Heart Association [AHA])
ecently announced new goals, one of
hich is to “eliminate waste while in-
uring the delivery of appropriate care”
15). Among the 9 areas targeted for a
0% reduction are unwarranted diag-
ostic procedures, including CTCA.
During the past decade, the cardio-
ascular community has often embraced
roader application of new technologies
s part of an “increase the volume/grow
he business” mentality, in response to
eclining rates of Medicare reimburse-
ents. The cardiovascular community
uickly embraced the use of pulsed
oppler and tissue Doppler echo pa-
ameters to assess the response to car-
iac resynchronization therapy. Despiteumerous reports that various parame-
ers were useful, a carefully conducted,
nternational, multicenter trial found
hat most of these parameters could not
e reproducibly measured, and that the
ingle parameter that was reproducible,
he left ventricular pre-ejection interval,
as not predictive of the response to
esynchronization therapy (16).
Our health care system cannot af-
ord to repeat this mistake with
TCA. As responsible stewards of
ur nation’s health care resources,
e must demand definitive evidence
hat CT coronary angiography has
dded value, either in improved pa-
ient outcomes, or reduced health
are costs, or in some combination
f the 2, before we adopt it on a
idespread basis.
xisting approach to the noninvasive as-
essment of CAD. There is a well-
stablished approach to the assessment of
atients with chest pain and known or
uspected CAD, which is reflected in
xisting clinical practice guidelines from
oth the ACC/AHA (17) and the Eu-
opean Society of Cardiology (ESC)
18). The first step in the evaluation of
uch patients is a careful history and
hysical examination to provide an esti-
ate of the pre-test likelihood of CAD.
he next step is often noninvasive stress
esting with an exercise ECG, stress
PECT MPI, or stress echocardiogra-
hy. These stress tests provide objective
vidence of ischemia to determine
hether the patient has functionally sig-
ificant CAD that likely explains his or
er symptoms. The test results can be
laced into 3 broad categories:
. When there is no evidence of ischemia,
the patient can be reassured that CAD
is not a likely cause of their symptoms,
and alternative diagnoses can be pur-
sued.
. When there is evidence of isch-
emia, but the test results are not
high risk, the patient can be man-
aged medically.
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311. When the test results show evi-
dence of ischemia and a high risk of
subsequent cardiac events, the pa-
tient should be referred for coro-
nary angiography.
Figure 3. Annual Growth in Health Care Spendin
from 1970 to 2004
Modiﬁed from Peter R. Orszag. CBO Testimony: H
for Reform. Washington, DC: United States Congr
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bons RJ. Asymptomatic patients with diabetes mell
ease. J Nucl Cardiol 2006;13:616–20.This strategy relies on an enormous
ublished evidence base over many de-
ades supporting the use of both the
xercise ECG and stress imaging. The
ldest portion of the evidence base relates
ublic and Private) and Gross Domestic Product
h Care and the Budget: Issues and Challenges
onal Budget Ofﬁce, 2007. Available at: http://
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should not be screened for coronary artery dis-eo the diagnosis of CAD, and is well
ummarized in multiple clinical practice
uidelines (Online Table 2). The evi-
ence supporting the prognostic value of
oth the exercise ECG and stress imag-
ng studies is equally robust, and probably
ven more important. Dozens of studies
n tens of thousands of patients have
onsistently shown that patients with
nown or suspected CAD who do not
ave demonstrable stress-induced isch-
mia have very low cardiac event rates
ver the next 3 to 7 years (Online Tables
to 5) (19). Revascularization will likely
ot reduce the rate of subsequent death
r myocardial infarction in such patients.
f their symptoms prove refractory to
edical therapy, they may require coro-
ary angiography, but the goal of revas-
ularization at that time will usually be to
educe symptoms rather than to improve
ard outcomes.
In contrast, patients with severe stress-
nduced ischemia have far higher rates of
ubsequent cardiac events and therefore
arrant early coronary angiography to
etermine whether they are candidates
or revascularization to improve their
utcomes. This strategy recognizes that
here will often be differences between
he functional significance of a coronary
esion and its anatomic appearance. The
ere presence of an anatomic lesion is
ot sufficient to justify revascularization,
s clearly reflected in existing clinical
ractice guidelines. The ESC Percutane-
us Coronary Intervention Guidelines
20) have a class I recommendation for
ercutaneous intervention in stable coro-
ary disease if there is “objective evidence
f a large area of ischemia.” The ACC/
HA/Society of Coronary Angiography
nd Intervention Percutaneous Coronary
ntervention Guidelines (21) have a class
Ia recommendation for patients who are
symptomatic or mildly symptomatic
hen the vessels “subtend a moderate to
arge area of viable myocardium
r. . .[are] associated with moderate or
evere degree of ischemia on noninvasive
esting.” Thus, objective demonstration
f stress-induced ischemia is a well-g (P
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312linical practice guidelines for the man-
gement of patients with chronic CAD.
T angiography compared with invasive
ngiography. In comparison, the pub-
ished evidence base supporting CTCA is
romising but limited. Multiple studies
ave shown that CTCA using the latest
Figure 5. Federal Spending in Medicare and Med
By 2047, these items will exceed 20% of gross dom
enue over the last 60 years has been between 17%
CBO Testimony: Health Care and the Budget: Issues
States Congressional Budget Ofﬁce, 2007. Available
HealthCareReform.pdf. Accessed February 8, 2010.
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Report OEI-01-06-00260. October 2007. Washington
2007. Available at: http://oig.hhs.gov/oei/reports/oei-014-slice scanners can produce results that
ompare favorably with ICA. A recent
ystematic review and meta-analysis (22)
nalyzed data from 28 studies in 1,286
atients, and reported a pooled sensitivity
f 99% and a pooled specificity of 89%.
owever, these studies have, by neces-
id as a Percentage of GDP
c product (GDP). By comparison total Federal rev-
20.9% of GDP. Modiﬁed from Peter R. Orszag.
Challenges for Reform. Washington, DC: United
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ar increase. Reproduced from Ofﬁce of the
nder the Medicare Physician Fee Schedule.
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-06-00260.pdf. Accessed February 8, 2010.ity, focused on patients referred for ICA.
uch patients are unlikely to reflect the
ull spectrum of patients with chest pain
nd known or suspected CAD. In gen-
ral, they are more likely to have a high
re-test likelihood of CAD, and prior
oninvasive tests showing ischemia.
Since publication of this meta-
nalysis, 2 significant additional studies
ave been reported. Budoff et al. (23)
ocused on patients with a low-to-
ntermediate risk of CAD in an impor-
ant effort to broaden the evidence base.
owever, this study only included 32
atients with significant CAD by the
sual 70% stenosis definition, a disease
revalence of 13.9% that is more “low”
han “intermediate.” This disease preva-
ence is surprisingly low for patients with
mean age of 58 years and symptoms of
ypical and atypical angina, raising some
oncern about the generalizability of the
esults. Moreover, given the limited
umber of patients with CAD in the
tudy, the lower 90% confidence limits
or sensitivity and specificity were 76%
nd 79%, respectively. The study, there-
ore, did not achieve its stated goal of
xcluding values80% for both sensitiv-
ty and specificity.
Miller et al. (24) reported results on
91 patients with calcium scores of 600
r less. The overall prevalence of signifi-
ant CAD was considerably higher at
6%, using a stenosis of greater than 50%
ccording to quantitative ICA. Although
T angiography did identify the pres-
nce and severity of obstructive CAD,
he PPV of 91% and NPV of 83% were
omewhat disappointing, and the authors
ppropriately concluded that “CT an-
iography cannot replace conventional
oronary angiography at present.”
The results of Miller et al. (24) were
onsistent with several previous studies in
he literature that found a limited associ-
tion between stenosis severity by CTCA
nd stenosis severity by ICA. In 2005,
eber et al. (25) reported a correlation
oefficient of only 0.54, and showed that
any stenoses judged to be 20% to 70%
y one approach were 0% by the otherica
esti
and
and
at:9
g by
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id U
, DCpproach. More recently, Meijboom et
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313l. (26) also reported a limited association
r  0.53), although they did not find
xamples of such extreme discordance.
T angiography compared with noninva-
ive stress testing. The more important
uestion for practicing physicians is not
hether CTCA will replace ICA, but
hether it will replace noninvasive stress
esting with or without imaging. What is
he evidence comparing 64-slice CT cor-
nary angiography with the approaches
ommonly used in clinical practice in the
ssessment of patients with known or
uspected CAD: the exercise ECG,
tress echocardiography, and stress
PECT MPI?
I am not aware of a single published
tudy comparing the exercise ECG with
4-slice CTCA. It is possible that I have
issed such studies, or that there are
omparative data incorporated in the re-
ults section of other reports.
Similarly, I am not aware of a single
ublished study comparing the results of
tress echocardiography with 64-slice CT
oronary angiography.
Finally, only a few studies have com-
ared 64-slice CT coronary angiography
ith SPECT MPI. Figure 7 shows 5
epresentative studies (27–31) that have
sed a standardized approach to SPECT
nd include sufficient detail to permit
alculation of PPV and NPV. Note that
total of only 385 patients are included.
nly 1 of these studies is from the U.S.
TCA does have a high NPV (i.e., the
bsence of obstructive disease by CT
ngiography is generally associated with
negative SPECT perfusion image).
owever, the NPV is not 100%. This
ould reflect false positive perfusion im-
ges, or the presence of true stress-
nduced ischemia in the absence of ob-
tructive disease, a well-established
henomenon (32,33). The PPV in these
tudies ranged from 45% to 67%. This
ay reflect the assessment of stenoses of
ntermediate severity, which might or
ight not be physiologically significant.
owever, several of these studies have
eported that severe stenoses by CT an-
iography were not associated with de- oectable ischemia in a considerable per-
entage of patients.
The spectrum of patients included in
hese limited studies is probably not rep-
esentative of the broad population of
atients with stable chest pain, as 2 of the
studies included patients with known
AD, and a majority of the patients in 3
f the studies were referred for invasive
ngiography.
As indicated earlier, the evidence base
upporting the prognostic value of non-
nvasive stress testing is at least as impor-
ant as those studies examining the diag-
ostic value of the exercise ECG and
tress imaging. What data are currently
vailable regarding the prognostic value
f CTCA in this regard? The available
ata have been well summarized else-
here (34). At this time, the only prog-
ostic studies with 64-slice CT angiog-
aphy have limited follow-up, as the
echnology only recently became avail-
ble. The only study with a mean
ollow-up of 5 years, a reasonable time
rame for chronic CAD, utilized electron
eam coronary angiography in a large
ohort, but the symptomatic status of the
atients was not reported (35).
ther concerns. Despite the health care
risis, and the limited evidence base in
upport of CTCA, some have continued
o argue for more widespread application
f this promising technology in the belief
hat the “evidence will certainly come.”
ven if one is willing to accept this
rgument, which I am not, there remain
ome important unresolved questions
hat must be answered before widespread
linical application.
How will we evaluate and manage
atients with discordant results by
TCA and stress imaging? Some pa-
ients will undergo anatomic assessment
sing CT coronary angiography and
unctional assessment using stress imag-
ng. The results will not always be con-
istent. As already mentioned, some pa-
ients with “moderate” stenosis by CT
oronary angiography will have func-
ional evidence of ischemia; some will
ot. How will we manage patients with-
ut functional ischemia: what follow-up nests will be performed, and at what
ntervals? Will clinicians feel compelled
o perform ICA in such patients to “clear
he air”? Van Werkhoven et al. (36) have
eported that 25% of patients with nor-
al stress SPECT images will have ob-
tructive CAD on CTCA; of these, 5%
ill have high-risk CAD. What will we
ell these patients? How will they be
anaged, both initially and over time?
How will we manage patients with
mild CAD” by CTCA? This finding
ight improve patient compliance with
ifestyle change and risk factor modifica-
ion to prevent both progression of CAD
nd future cardiac events. However, it
ill also increase anxiety in a subset of
atients, who realize for the first time
hat they have atherosclerosis. Will such
atients demand or expect routine
ollow-up studies by CTCA to make
ertain that their disease has not pro-
ressed? To contemplate using CTCA
or this purpose, we would need a lot
ore information about its reproducibil-
ty for the assessment of mild-to-
oderate stenoses. Without this infor-
ation, it will be impossible to judge
hether a change over time really repre-
ents a change in the patient’s lesion.
Will CT coronary angiography re-
uce the subsequent rate of ICA? This
s often assumed to be the case. There
re two published observational studies
37,38) suggesting that the use of
TCA may help to clarify “equivocal”
r “intermediate-risk” SPECT MPI
mage results and thereby avoid ICA.
owever, given the poor association
etween the severity of stenosis by
TCA and ICA, will there be patients
ith “mild” disease by CTCA who are
hen referred to ICA? As I have de-
ailed elsewhere (19), I have already
een an example in another medical
enter of just such a patient, who then
nderwent immediate intervention
ithout any documentation of ischemia
r symptoms. A carefully conducted
egional study from Canada with con-
emporary controls (39) demonstrated
hat the rate of normal invasive coro-
ary angiograms decreased after intro-
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314uction of CTCA into their practice,
ut the overall rate of ICA increased.
Finally, there is the question of
opulation radiation burden. In expe-
ienced hands, prospective gating can
reatly decrease the radiation expo-
ure involved in CTCA to a range
hat is similar to SPECT MPI. How-
ver, without these measures, the ra-
iation exposure and risk will be con-
iderably higher, particularly in young
omen. If CTCA becomes “the stan-
ard” for evaluating episodes of chest
ain, how frequently will it be re-
eated in young women with atypical
ymptoms? Despite convincing pub-
ished evidence that the “warranty
eriod” for a normal exercise SPECT
tudy in a patient without known
0
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Figure 7. PPV and NPV for 4 Representative Ser
Positive predictive value (PPV) and negative predictiv
the recent literature comparing 64-slice computed to
protocol for myocardial perfusion imaging. Modiﬁed w
Carli MF. Myocardial perfusion imaging and multidetect
priate for all patients with suspected coronary artery disAD is greater than 5 years in young t
ity, Lower Costs Throughout Americanatients without diabetes, preliminary
ata from our laboratory (40) shows
hat 91% of the “routine” follow-up
PECT studies conducted in such
atients are done before expiration of
he warranty period. When will clini-
ians order follow-up CTCA in the
bsence of evidence about the “war-
anty period” of CT angiography in
ymptomatic patients?
eed for future studies. CTCA is a
ery promising technology that merits
nd demands future study. Shah et al.
41) have described the possible pa-
ameters for a carefully designed pro-
pective study of CTCA for the diag-
osis of CAD. I have personal
nowledge of 2 other proposals for
imilar studies that were submitted to
li et al:
2008
8
Seto et al:
JNM, 2008
n=104
Haramati et al:
Int J. Card Imag, 2009
n=61
NPV
lue (NPV) for 4 representative series (78–81) from
raphy coronary angiography with a standardized
permission from Dorbala S, Hachamovitch R, Di
mputed tomographic coronary angiography: appro-
? J Am Coll Cardiol 2006;48:2515–7.he National Heart, Lung, and Blood g
sociation Task Force on Practice Guidelinesnstitute this year. The design of a
tudy of CTCA in patients with pe-
ipheral vascular disease has also been
ublished (42). These are the kind of
rospective, multicenter, “real-world”
tudies that need to be done before
TCA is adopted on a widespread
asis. Congress has recognized the
eed for increased federal funding for
omparative effectiveness research.
he economic stimulus package
igned into law included 1.1 billion
ollars in incremental funding to the
gency for Healthcare Research and
uality, the National Institutes of
ealth, and the Secretary of Health
nd Human Services to help support
uch research. I personally hope that
ome of this incremental funding helps
o support future studies of CTCA. The
uture of this promising technology, as
ell as the growing crisis in health care in
ur country, demand it. We as evidence-
ased physicians should await the results
f these studies before embracing CTCA
n a widespread basis. It is not yet ready
or prime time.
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